Pharmaceutical intermediates
Lenalidomide Intermediates
2 pharmaceutical intermediates for Lenalidomide. Indication: Marginal zone B-cell lymphoma; Diffuse large B-cell lymphoma; Adult T-cell leukemia lymphoma; Multiple myeloma.
About Lenalidomide
- Originator
- Celgene Corporation
- Indication
- Marginal zone B-cell lymphoma; Diffuse large B-cell lymphoma; Adult T-cell leukemia lymphoma; Multiple myeloma
- Approved Date
- 06/29/2006
- DS/DP
- 04/27/2027
Available intermediates
2 intermediates currently listed for Lenalidomide. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| methyl 2-(bromomethyl)-3-nitrobenzoate | 98475-07-1 | / | / |
| 3-aminopiperidine-2,6-dione hydrochloride | 24666-56-6/2686-86-4 | / | / |
Building toward Lenalidomide?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →